
Throughout November, December And January, All Donations Made To Parasites Without Borders Will Be Matched By PWB And Donated To MicrobeTV
August 20, 2022
Public Health Response to a Case of Paralytic Poliomyelitis in an Unvaccinated Person and Detection of Poliovirus in Wastewater | Human-to-human transmission of monkeypox virus | What to Do If You Were Exposed to COVID-19 and its Isolation and Precautions for People with COVID-19 | Tecovirimat and the Treatment of Monkeypox — Past, Present, and Future Considerations | Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U.S. FDA | Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment
August 13, 2022
Interim Guidance for Prevention and Treatment of Monkeypox in Persons with HIV Infection — United States, August 2022 | Post–COVID-19 Symptoms and Conditions Among Children and Adolescents — United States, March 1, 2020–January 31, 2022 | Profiling post-COVID syndrome across different variants of SARS-CoV-2 | Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects | Viral Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Infection in mRNA-Vaccinated Individuals Treated and Not Treated with Nirmatrelvir-Ritonavir
August 6, 2022
Viral and Symptom Rebound in Untreated COVID-19 Infection | Cognitive Impairment 13 Months After Hospitalization for COVID-19 | Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld©) for COVID-19 among 1112 severely immunocompromised patients | Extended Remdesivir Infusion for Persistent COVID-19 Infection | Association between AZD7442 (tixagevimab-cilgavimab) administration and SARS-CoV-2 infection, hospitalization and mortality | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomized, controlled, open-label, platform trial and updated meta-analysis
July 28, 2022
Symptoms and risk factors for long COVID in non-hospitalized adults | Post–COVID-19 Conditions Among Children 90 Days After SARS-CoV-2 Infection | Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022 | Pregnancy outcomes after SARS-CoV-2 infection by trimester: A large, population-based cohort study
July 21, 2022
Children and COVID-19: State level Data Report | SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses | Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages | CDC Recommends Novavax’s COVID-19 Vaccine for Adults | Paxlovid in patients who are immunocompromised and hospitalized with SARS-CoV-2 infection | Inhaled Fluticasone for Outpatient Treatment of Covid-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial
July 14, 2022
Neurovascular injury with complement activation and inflammation in COVID-19 | Factors Associated with Severe Outcomes Among Immunocompromised Adults Hospitalized for COVID-19 — COVID-NET, 10 States, March 2020–February 2022 | Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, & BA.5 | Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants | Parental COVID-19 Vaccine Hesitancy in Diverse Communities: A National Survey | Oral Sabizabulin for High-Risk, Hospitalized Adults with Covid-19: Interim Analysis | Rapid Diagnostic Testing for Response to the Monkeypox Outbreak — Laboratory Response Network, United States, May 17–June 30, 2022
Situation Dashboards

World Health Organization (WHO)
Novel Coronavirus (COVID-19) Situation from World Health Organization (WHO)

Johns Hopkins University (JHU)
Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at JHU

COVID-19 in US and Canada
1Point3Acres Real-Time Coronavirus (COVID-19) Updates in US and Canada with Credible Sources

Genomic Epidemiology COVID-19
Genomic Epidemiology of (COVID-19) Maintained by the Nextstrain team, enabled by data from GISAID.